scholarly journals Albendazole in malignant ascites: a case report and literature review on the successes and adverse effects of therapy

2021 ◽  
Vol 8 (10) ◽  
pp. 3146
Author(s):  
Jasmine J. Mui ◽  
David Morris
Keyword(s):  
Hepatic Metastases ◽  
Malignant Ascites ◽  
Adverse Outcomes ◽  
Vascular Endothelial ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Significant Burden ◽  
Endothelial Growth Factor

Malignant ascites places a significant burden on the healthcare system and has a profound effect on patient quality of life. Albendazole (ABZ) is an anti-helminthic agent that has shown to rapidly reduce malignant ascites with minimal side effects in pre-clinical trials. The following case study explores the effect of ABZ on ascitic volume in a patient with malignant ascites secondary to metastatic colorectal adenocarcinoma. The patient is a 54-year-old man who underwent an ultrasound guided ascitic drainage for worsening ascites secondary to hepatic metastases from sigmoid adenocarcinoma. He was commenced on ABZ based on literature demonstrating that ABZ decreases the volume of malignant ascites via the inhibition of vascular endothelial growth factor. Over the next week, the volume of ascitic fluid decreased significantly, however the patient developed neutropenia unresponsive to granulocyte colony stimulating factor likely in the context of impaired liver function. The efficacy of ABZ in this case study as well as in the literature demonstrates the promising potential for use in reducing malignant ascites. However, this case demonstrates the need for caution for use in patients with liver impairment due to changes to first pass metabolism leading to increased circulating drug toxicity and thus, adverse outcomes.  

Visibility Analysis for Assembly Fixture Calibration Using Screen Space Transformation

2003 ◽  
Author(s):  
Zhenyu Kong ◽  
Wenzhen Huang ◽  
Dariusz Ceglarek
Keyword(s):  
Visibility Analysis ◽  
Space Transformation ◽  
Significant Burden ◽  
New Type ◽  
Quality Of Products ◽  
Screen Space ◽  
Calibration Time ◽  
Assembly Fixture

In a number of manufacturing processes, tooling installation, calibration and maintenance guarantee the precision of fixtures and play important roles towards the overall quality of products. Recently a new type of measurement equipment called “laser tracker” was developed and utilized for assembly fixture calibration to shorten calibration time and improve the accuracy of the currently used theodolite systems. Though, the calibration of assembly fixture is critical for product quality, the calibration time creates significant burden for productivity of multi-station assembly processes. In order to shorten the calibration lead time, the number of necessary calibration setups which is determined by visibility analysis needs to be minimized. This paper presents a screen space transformation based visibility analysis that allows minimizing the number of setups. The screen space transformation is applied to transform the visibility problem from 3D to 2D space, consequently the visibility problem can be solved efficiently. A case study illustrates the procedure and verifies the validity of the proposed methodology.

scholarly journals Mobilizing for Community Benefits to Assess Health and Promote Environmental Justice near the Gordie Howe International Bridge

2020 ◽  
Vol 17 (13) ◽  
pp. 4680
Author(s):  
Natalie Sampson ◽  
Simone Sagovac ◽  
Amy Schulz ◽  
Lauren Fink ◽  
Graciela Mentz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Environmental Justice ◽  
Community Engagement ◽  
Health Care Access ◽  
Survey Methods ◽  
Household Survey ◽  
Adverse Outcomes ◽  
Community Benefits

Transportation infrastructure decisions contribute to social, economic, and health inequities in the U.S. Health Impact Assessments (HIAs) may improve understanding of potential strategies to mitigate adverse effects on quality of life from planned developments. We use the Gordie Howe International Bridge (GHIB), currently under construction in southwest Detroit, MI, as a case study to examine 15 years of community mobilization, which resulted in community benefits that included an HIA. We describe community engagement processes, household survey methods, and select findings of the baseline HIA, with a focus on their application to inform recommendations to promote quality of life. Baseline HIA results indicated significantly higher self-reported asthma rates among children living within 500 feet of trucking routes. Residents reported substantial economic (e.g., decreased home values), health (e.g., adverse outcomes, lack of health care access), and environmental (e.g., air pollution) concerns related to the GHIB. We discuss specific recommendations, based on HIA results, to reduce adverse impacts of the GHIB. These recommendations will inform ongoing community benefits negotiations. This case study provides lessons for community, academic, and government partners conducting HIAs, especially during building and operation of major infrastructure, and discusses their potential role in improving community engagement opportunities towards environmental justice.

scholarly journals Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer

PLoS ONE ◽  
2014 ◽  
Vol 9 (7) ◽  
pp. e101145 ◽  
Author(s):  
Labib Imran Faruque ◽  
Meng Lin ◽  
Marisa Battistella ◽  
Natasha Wiebe ◽  
Tony Reiman ◽  
...  
Keyword(s):  
Systematic Review ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Adverse Outcomes ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Combination of pegylated-liposomal doxorubicin (PLD) and bevacizumab (B) (PLD-B) in sarcoma (SAR)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 20506-20506
Author(s):  
K. M. Skubitz ◽  
P. A. Haddad
Keyword(s):  
Dose Reduction ◽  
Pegylated Liposomal Doxorubicin ◽  
Skin Toxicity ◽  
Symptomatic Improvement ◽  
Vascular Endothelial ◽  
Toxicity Profile ◽  
Median Dose ◽  
Starting Dose ◽  
Endothelial Growth Factor

20506 Background: Vascular endothelial growth factor (VEGF) plays an important role in many tumors including SAR. Because of the known efficacy of PLD in SAR and the presumed importance of VEGF in SAR, we have treated SAR patients with PLD-B. It is possible that the addition of B to PLD might alter the toxicity profile. The toxicities of this combination are not well described. Methods: To better define the toxicity of the combination of PLD-B in SAR, we reviewed our experience with PLD-B in patients treated between 2004 and 2006. Results: We identified 20 patients with SAR treated with PLD-B at our institution. There were 9 men and 11 women, with a median age of 47.5 years (range 23–77). Ten patients initiated therapy with PLD q28 days at a median dose of 45 mg/m2 (range 45–50), and 10 q14 days at a median dose of 21.2 mg/m2 (range 20–25), in combination with B at 5 mg/kg q14 days. A median of 5 cycles was given (range 1–15). Dose delay was required in 3 patients for the second cycle, and dose reduction was required in 9 patients by cycle 3. Of the 10 patients starting with monthly PLD, 7 were changed to q14 day PLD by cycle 4. Mucositis and skin toxicity were the dose limiting toxicities (DLT) in 14/20 patients, and myelosuppression was the DLT in 1/20 patients. Nine patients were felt to have clinical benefit; 3 had a PR and 6 had SD. Notably, 2/4 recurrent Ewing sarcoma patients had symptomatic improvement and at least SD for 10 and 11 months, respectively, with minor toxicity allowing a good quality of life. Conclusions: This report describes the toxicity profile of PLD-B in 20 patients with SAR. The toxicities observed were similar to those seen with PLD alone, however, these toxicities appeared more pronounced with the addition of B. Since VEGF is important for wound healing, the known effects of B on this process may contribute to more skin and mucosal toxicity of PLD at a given dose. Future studies of PLD-B should consider the potential of increased mucosal and skin toxicity. The use of q14 day PLD to allow more control over toxicity is suggested; a maximal starting dose of 20 mg/m2 is reasonable, although dose reduction will be common due to skin or mucosal toxicity. This combination can be given with limited toxicity, and meaningful responses were observed in recurrent sarcomas, including 2/4 Ewing sarcomas. No significant financial relationships to disclose.

Quality of life, vascular endothelial growth factor inhibition, and survival outcomes with combination oral metronomic therapy in platinum refractory epithelial ovarian carcinoma: Results from a randomized study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 6048-6048
Author(s):  
Aparna Sharma ◽  
Sachin Khurana ◽  
Prabhat Singh Malik ◽  
Mayank Singh ◽  
Sandeep Mathur ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Histopathological Diagnosis ◽  
Vascular Endothelial ◽  
Patient Reported ◽  
Platinum Refractory ◽  
Metronomic Therapy ◽  
Endothelial Growth Factor

6048 Background: Patients with recurrent and refractory epithelial ovarian cancer (EOC) have dismal outcomes. We evaluated a combination of oral metronomic therapy in platinum refractory EOC vis-à-vis angiogenic marker expression and its impact on patient reported outcomes. Methods: Between October 2017 and September 2019, 75 patients were randomized to receive etoposide (VP-16) (50 mg daily for 14 days) cyclophosphamide (50 mg daily for 28 days) (Arm A, n = 38) or etoposide (VP-16) (50 mg daily for 14 days) cyclophosphamide (50 mg daily for 28 days) and pazopanib (400 mg daily 28 days) every 28 days (Arm B, n = 37). Eligibility criteria included histopathological diagnosis of EOC, platinum refractory disease and ECOG performance status 0-2. Primary endpoint was serological progression free survival (PFS) as defined by Rustin criteria. Quality of Life (QoL) (evaluated using the EORTC QLQC30 and OV 28 questionnaires) and serum vascular endothelial growth factor (VEGF) were ascertained at baseline and after 3rd and 6th cycle. Intention to treat analysis was done. Results: Baseline characteristics were well matched in 2 arms. At a median follow up 14.4 months (95% CI 13.2-15.7), the median serological PFS is better for patients in Arm B 5.1 months (95%CI 3.13-10.33) compared to 3.4 months (95%CI 3-6.53) in arm A ( P= 0.045). Median overall survival (OS) is not reached in arm B versus 11.2 months (95%CI 5.66-NR) in arm A (P= 0.032). Disease progression was seen in 42.1% (n = 16) in Arm A versus 40.5 %(n = 15) in arm B ( P= 0.40). Sixteen patients are maintaining response. Mucositis (29.7% n = 11) and fatigue (13.5%, n = 5) were more in the pazopanib-containing arm ( P= 0.36). Serum VEGF demonstrated significant decline with subsequent cycles of therapy {median values (range): Arm A, baseline; 466.0 pg/mL(123.9-1930) vs. 6 cycles; 92.05pg/ mL(42.34-279.5) P< 0.0001; Arm B, baseline; 382.0 pg/mL(49.44-2054.0) vs 6 cycles; 119.7 pg/mL(18.20-367.5) P= 0.013} without any difference between the two arms ( P= 0.18). QoL symptom scales in both QLQC 30 and OV 28 questionnaires indicated small but significant improvement in pazopanib arm ( P= 0.02) without differences in global (p = 0.96) and physical functioning scales. ( P= 0.68). Conclusions: Addition of pazopanib to etoposide and cyclophosphamide resulted in improvement in serological PFS and OS with a well-tolerated toxicity profile and modest improvement in QoL.Serum VEGF expression requires validation in a larger cohort. Clinical trial information: CTRI/2017/10/010219.

Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites

1999 ◽  
Vol 6 (4) ◽  
pp. 373-378 ◽  
Author(s):  
Brian K. Zebrowski ◽  
Wenbiao Liu ◽  
Karen Ramirez ◽  
Yoshito Akagi ◽  
Gordon B. Mills ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Malignant Ascites ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Multidisciplinary Management of Advanced Kidney Cancer

2020 ◽  
Vol 18 (7.5) ◽  
pp. 977-981
Author(s):  
Chad A. LaGrange ◽  
M. Dror Michaelson ◽  
Colleen H. Tetzlaff
Keyword(s):  
Kidney Cancer ◽  
Survival Rates ◽  
Vascular Endothelial ◽  
Multidisciplinary Management ◽  
Close Attention ◽  
Therapy Options ◽  
Endothelial Growth Factor ◽  
Choice Of Therapy ◽  
Overall Survival Rates

A number of therapeutic options are available for the treatment of advanced kidney cancer, including targeted therapy, immunotherapy, and nephrectomy. Choice of therapy for advanced kidney cancer is guided by risk stratification. Immunotherapy combinations are generally superior to vascular endothelial growth factor -based monotherapy, and overall survival rates continue to increase substantially. With new systemic therapy options, additional improvements have been noted in durable responses to treatment and in quality of life. Nephrectomy remains an important consideration in selected patients, particularly those with minimal burden of metastatic disease. Managing the adverse events of treatment of advanced kidney cancer requires close attention and multidisciplinary collaboration.

Sign in / Sign up

Export Citation Format

Share Document